Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05418582 · ClinicalTrials.gov registry record · Phase 1

Drug-drug Interactions Between DZD9008 and Itraconazole/Carbamazepine

A Phase 1 study, sponsored by Dizal Pharmaceuticals.

Completed
Registry status
Phase 1
Development phase
40
Enrollment target

NCT05418582: Completed Phase 1 study, sponsored by Dizal Pharmaceuticals.

NCT05418582 is a Phase 1 study that has completed, run by Dizal Pharmaceuticals. The registered enrollment target is 40 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05418582, a Phase 1 study, has completed, sponsored by Dizal Pharmaceuticals.

COMPLETED
Registry status
Phase 1
Development phase
40 participants
Enrollment target

Study Summary

This is a Phase 1, single-center, nonrandomized, open-label, 2-part, fixed-sequence, drug-drug interaction (DDI) study to assess the effect of multiple doses of itraconazole, a CYP3A4 enzyme inhibitor, on the single dose PK of DZD9008 in healthy adult subjects (Part A) and to assess the effect of multiple doses of carbamazepine, a CYP3A4 inducer, on the single dose PK of DZD9008 in healthy adult subjects (Part B).

Interventions

  • DRUG DZD9008 and intraconazole
  • DRUG DZD9008 and carbamazepine

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2022-01-25
Est. Completion 2022-12-08
Phase Phase 1
Dizal Pharmaceuticals

15 total trials

What the finished NCT05418582 record still lists

NCT05418582 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% lower).

The record links to 0 conditions, and to 2 interventions - of which DZD9008 and intraconazole is the first listed.

NCT05418582 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT05418582 about?

NCT05418582 is a clinical study titled "Drug-drug Interactions Between DZD9008 and Itraconazole/Carbamazepine". This is a Phase 1, single-center, nonrandomized, open-label, 2-part, fixed-sequence, drug-drug interaction (DDI) study to assess the effect of multiple doses of itraconazole, a CYP3A4 enzyme inhibitor, on the single dose PK of DZD9008 in healthy adult subjects (Part A) and to assess the effect of mu...

What is the current status of trial NCT05418582?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2022-01-25. Estimated completion is 2022-12-08.

What interventions are being tested in trial NCT05418582?

The interventions under investigation include: DZD9008 and intraconazole (DRUG), DZD9008 and carbamazepine (DRUG).

Who is sponsoring clinical trial NCT05418582?

This trial is sponsored by Dizal Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT05418582's enrollment target sits among peer trials

40 1130th of 2000 higher than 810 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05418582, the US trial registry maintained by the National Library of Medicine. NCT05418582 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.